AU2014368927B2 - Cancer treatments using combinations of CDK and ERK inhibitors - Google Patents

Cancer treatments using combinations of CDK and ERK inhibitors Download PDF

Info

Publication number
AU2014368927B2
AU2014368927B2 AU2014368927A AU2014368927A AU2014368927B2 AU 2014368927 B2 AU2014368927 B2 AU 2014368927B2 AU 2014368927 A AU2014368927 A AU 2014368927A AU 2014368927 A AU2014368927 A AU 2014368927A AU 2014368927 B2 AU2014368927 B2 AU 2014368927B2
Authority
AU
Australia
Prior art keywords
asp
val
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014368927A
Other languages
English (en)
Other versions
AU2014368927A1 (en
Inventor
Gary Decrescenzo
Jeffrey James ROIX
Saurabh Saha
Dean WELSCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomed Valley Discoveries Inc
Original Assignee
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc filed Critical Biomed Valley Discoveries Inc
Publication of AU2014368927A1 publication Critical patent/AU2014368927A1/en
Application granted granted Critical
Publication of AU2014368927B2 publication Critical patent/AU2014368927B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2014368927A 2013-12-20 2014-12-19 Cancer treatments using combinations of CDK and ERK inhibitors Active AU2014368927B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919597P 2013-12-20 2013-12-20
US61/919,597 2013-12-20
PCT/US2014/071747 WO2015095840A1 (en) 2013-12-20 2014-12-19 Cancer treatments using combinations of cdk and erk inhibitors

Publications (2)

Publication Number Publication Date
AU2014368927A1 AU2014368927A1 (en) 2016-07-21
AU2014368927B2 true AU2014368927B2 (en) 2018-10-25

Family

ID=53403797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014368927A Active AU2014368927B2 (en) 2013-12-20 2014-12-19 Cancer treatments using combinations of CDK and ERK inhibitors

Country Status (6)

Country Link
US (5) US11013743B2 (OSRAM)
EP (2) EP3082423B1 (OSRAM)
JP (1) JP6678584B2 (OSRAM)
AU (1) AU2014368927B2 (OSRAM)
ES (1) ES3033810T3 (OSRAM)
WO (1) WO2015095840A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PE20180318A1 (es) 2011-01-10 2018-02-09 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017021177A1 (en) * 2015-08-04 2017-02-09 Universitat De Barcelona Pharmaceutical combinations for use in the treatment of cancer
JP2018526377A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
KR20230020549A (ko) * 2016-03-24 2023-02-10 코테라 바이오사이언스 인코포레이티드 Tg02를 사용한 암의 치료
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
WO2018081204A1 (en) * 2016-10-26 2018-05-03 Li George Y DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE
CN110799245B (zh) * 2017-05-16 2022-08-09 生物医学谷探索股份有限公司 用于治疗具有非典型braf突变的癌症的组合物和方法
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
JP2019116429A (ja) * 2017-12-26 2019-07-18 国立大学法人名古屋大学 抗ウイルス薬
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
JP7698418B2 (ja) * 2018-03-13 2025-06-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｅｇｆｒ活性化変異を有するがんを治療するための方法
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
SG11202101397TA (en) 2018-08-13 2021-03-30 Beijing Percans Oncology Co Ltd Biomarkers for cancer therapy
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
CN114040764A (zh) * 2019-02-15 2022-02-11 因赛特公司 细胞周期素依赖性激酶2生物标记物及其用途
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
MX2022004390A (es) 2019-10-11 2022-08-08 Incyte Corp Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2).
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN117224545A (zh) * 2023-09-26 2023-12-15 中国人民解放军陆军军医大学第二附属医院 Aminopurvalanol A在制备治疗肺腺癌的药物中的应用
WO2025111447A1 (en) * 2023-11-21 2025-05-30 Florida Atlantic University Board Of Trustees Treatment of cancer with drug combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354939B2 (en) * 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0689610B1 (en) 1993-03-19 2002-07-03 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
KR20100025553A (ko) * 2007-06-05 2010-03-09 쉐링 코포레이션 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
CN102186856B (zh) * 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
WO2010062546A1 (en) 2008-10-27 2010-06-03 Qiagen Gaithersburg Inc. Fast results hybrid capture assay on an automated platform
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354939B2 (en) * 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORRIS ET AL., "Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors", CANCER DISCOVERY, (201307), pages 742 - 750 *

Also Published As

Publication number Publication date
WO2015095840A1 (en) 2015-06-25
US11135225B2 (en) 2021-10-05
EP3082423A1 (en) 2016-10-26
EP4512480A2 (en) 2025-02-26
AU2014368927A1 (en) 2016-07-21
US11013743B2 (en) 2021-05-25
US20210393637A1 (en) 2021-12-23
EP3082423B1 (en) 2024-12-11
US11679112B2 (en) 2023-06-20
ES3033810T3 (en) 2025-08-08
US20240374604A1 (en) 2024-11-14
US20240033267A1 (en) 2024-02-01
US12076324B2 (en) 2024-09-03
EP4512480A3 (en) 2025-05-07
US20160317538A1 (en) 2016-11-03
JP2017502013A (ja) 2017-01-19
EP3082423A4 (en) 2017-09-20
US20200297730A1 (en) 2020-09-24
JP6678584B2 (ja) 2020-04-22

Similar Documents

Publication Publication Date Title
AU2014368927B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
EP3082800B1 (en) Cancer treatment using combinations of erk and raf inhibitors
AU2018269982B2 (en) Compositions and methods for treating cancer with atypical BRAF mutations
EP3082779B1 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
KR20230025941A (ko) 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
WO2015095807A1 (en) Cancer treatments using combinations of egfr and erk inhibitors
US20160310477A1 (en) Cancer treatments using combinations of mek type 1 and erk inhibitors
HK40108769A (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
HK40068070B (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
HK40068070A (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
HK40120025A (en) Cancer treatments using combinations of cdk and erk inhibitors
HK40075625A (en) Cancer treatment using combinations of erk and raf inhibitors
HK1226252B (en) Cancer treatments using combinations of cdk and erk inhibitors
HK1226252A1 (en) Cancer treatments using combinations of cdk and erk inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)